Nymox Drops Delaware Matter Against Ascella: What Does This Mean for Shareholders and the World? In a recent development, Irvine, California-based biotech company Nymox (NYMX) announced on March 11, 2025, that it had dismissed the Delaware matter pending against Ascella Biotech, a subsidiary of Nymox. The dismissal came on March 7, 2025, after careful consideration…
The Bell2Bell Podcast: Insights from Fast-Moving Industries Austin, Texas, Feb. 11, 2025 – IBN, a leading communications organization, is thrilled to announce the latest episode of The Bell2Bell Podcast. This podcast series is dedicated to bringing you informative updates and exclusive interviews with executives from various industries, keeping you connected to the latest trends and…
Shifting Priorities: The Federal Reserve and Inflation, McDonald’s Earnings Amid Challenges The Federal Reserve, the central banking system of the United States, has been making headlines recently due to its shifting focus from full employment to price stability. This shift comes as January’s Consumer Price Index (CPI) is expected to show persistent inflation. Inflation, a…
Southwest Gas Holdings Reports Fourth Quarter and Full-Year 2024 Financial Results Southwest Gas Holdings, Inc. recently announced its financial results for the fourth quarter and full-year ended December 31, 2024. The company reported a consolidated net income of $92.5 million, or $1.28 per diluted share, and an adjusted consolidated net income of $100.1 million, or…
Solana Shines in Q4 2024, Becoming a DeFi Powerhouse A recent report by market intelligence firm Messari has highlighted an extraordinary performance by Solana (SOL) during the fourth quarter of 2024, characterizing it as potentially the best quarter for any blockchain in history. Solana, a high-performance blockchain platform known for its fast and low-cost transactions,…
UPCOMING EVENTS Monday: US ISM Services PMI Tuesday: RBA Policy Announcement Wednesday: BoC Policy Announcement Thursday: US Jobless Claims Monday: The ISM Services PMI is expected to come a tick lower at 51.8 vs. 51.9 prior. The market will focus particularly on the prices paid side as core inflation remains stickier much above the Fed’s…
A Game-Changer in Rare Obesity Treatment: Rhythm Pharmaceuticals’ Experimental Drug In a groundbreaking development, Rhythm Pharmaceuticals, a leading biopharmaceutical company, announced on Monday that its experimental drug, setmelanotide, has met the primary endpoint in a pivotal late-stage clinical trial for the treatment of a rare and complex form of obesity known as Proprotein Convertase Subtilisin/Kexin…
Welcome to our Blog Post! Investigating Potential Claims Against Kaspi.kz Attorney Advertising – Bronstein, Gewirtz & Grossman, LLC is currently investigating potential claims on behalf of purchasers of Joint Stock Company Kaspi.kz (“Kaspi” or “the Company”) (NASDAQ: KSPI). If you have invested in Kaspi securities, we encourage you to obtain additional information and assist with…
